Endorphin patterns within the headache spectrum disorders.

Endorphin patterns within the headache spectrum disorders. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Endorphin patterns within the headache spectrum disorders. Abstract Text:

G Nappi,F Facchinetti,E Martignoni,F Petraglia,G C Manzoni,G Sances,G Sandrini,A R Genazzani,

The role of opioid peptides in modulating the nervous system adaptability has been demonstrated recently; proopiomelanocortin (POMC)-related peptides, in particular, serve in pain perception, in adaptation to stress, and in modulating higher brain functions. Primary headaches, besides pain, involve neuroendocrine/autonomic/adaptive processes as well as mood and personality factors. The view that primary headaches can be taken as a possible model of POMC-related peptides dysfunction led us to evaluate the resting plasma and CSF peptide levels and their plasma changes in response to various stimuli affecting their release. The data obtained from basal and dynamic studies agree with the concept that primary headaches are sustained by opioid system disturbance. In particular the reduced release of endogenous opioids by anterior pituitary in response to physical, endocrine or pharmacological stimuli agrees with a weak adaptive ability of headache sufferers. This impairment of endorphin responsiveness could play a key role in headache susceptibility to environmental stimuli. Primary headaches constitute a wide, intriguing field, including several subgroups bordering on "ischemic" and behavioral/affective disorders. The development of neuroendocrine techniques could be a useful means for supporting the clinical criteria identifying subpopulations of headache sufferers.

Endorphin patterns within the headache spectrum disorders. Publishing Authors By Initials

G Nappi,F Facchinetti,E Martignoni,F Petraglia,GC Manzoni,G Sances,G Sandrini,AR Genazzani,

For similar hormones, hormone substitutes, and hormone antagonists: hormones: peptide hormones: hypothalamic hormones: pro-opiomelanocortin: beta-endorphin research abstracts see: hormones, hormone substitutes, and hormone antagonists: hormones: peptide hormones: hypothalamic hormones: pro-opiomelanocortin: beta-endorphin research

PUBMED ID PMID:

MEDLINE DATE:

Endorphin patterns within the headache spectrum disorders. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Cephalalgia : an international journal of headache

VOLUME: 5 Suppl 2

Page Numbers: 201-10

Journal Abbreviation: Cephalalgia

ISSN: 0333-1024

DAY: 11

MONTH: May

YEAR: 1985

Endorphin patterns within the headache spectrum disorders. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8200710

Endorphin patterns within the headache spectrum disorders. Keywords Mesh Terms:

KEYWORDS: beta-Endorphin

MESH TERMS: cerebrospinal fluid

Chemical & Substance for Abstract: Endorphin patterns within the headache spectrum disorders. Information

Substance Name: Adrenocorticotropic Hormone

Registry Number: 9002-60-2

Grant and Affiliation Information for Endorphin patterns within the headache spectrum disorders.

AFFILIATION:

Country: NORWAY

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cephalalgia

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Endorphin patterns within the headache spectrum disorders Related Publications

• 5-hydroxytryptamine(1B) receptor and triptan response in migraine, lack of association with common polymorphisms.
• A case of acro-cephalo-syndactylia [Hebrew text].
• Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
• Brain derived neurotrophic factor circulating levels in patients undergoing IVF.
• Brain recurrences in patients with ovarian cancer: report of 12 cases and review of the literature.
• CSF beta-EP in headache and depression.
• Calcineurin primes immature gonadotropin-releasing hormone-secreting neuroendocrine cells for migration.
• Characterization of NAD Uptake in Mammalian Cells.
• Circadian variations of proopiocortin-related peptides in children with migraine.
• Click chemistry reactions in medicinal chemistry: Applications of the 1,3-dipolar cycloaddition between azides and alkynes.
• Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: The brain and the vessels.
• Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions.
• Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention.
• Endogenous opioid inhibitory tone on LH secretion in normal puberty and in several pubertal disturbances.
• Endorphin patterns within the headache spectrum disorders.
• Evaluation of central opioid tonus in menstrual migraine.
• Functional hypothalamic amenorrhea: Current view on neuroendocrine aberrations.
• Involvement of serotonin in the central control of opioid secretion.
• Naloxone test in primary headache sufferers.
• Neuroendocrine effects of flunarizine treatment in postmenopausal women.
• Opioid control of the hypothalamus-pituitary-adrenal axis cyclically fails in menstrual migraine.
• P26.08: Bilateral hemorrhagic fetal ovarian cyst: a case report.
• P26.12: Prenatal sonographic features of chloride diarrhea.
• Primary headaches: reduced circulating beta-lipotropin and beta-endorphin levels with impaired reactivity to acupuncture.
• Reduced testosterone levels in cluster headache: a stress-related phenomenon?
• Sympathergic/neuroendocrine reactivity as a marker of adaptive processes underlying migraine susceptibility.
• The association of menstrual migraine with the premenstrual syndrome.
• The management of patients with uterine sarcoma: A debated clinical challenge.
• The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature.
• Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.